How Biotech Startups Use AI to Predict Clinical Trial Outcomes

Episode 12 of Biotech Business with Fexingo. Lucas and Luna dive into the emerging practice of using artificial intelligence to predict whether a drug candidate will succeed in clinical trials before human testing begins. They focus on the startup VeriSIM Life, which builds digital models to simulate drug behavior across different patient populations—a process often called 'virtual patients.' The hosts break down how VeriSIM's AI platform, which integrates data from failed trials, public databases, and molecular simulations, can reduce the time and cost of drug development by flagging likely failures early. They also discuss the limitations: the models are only as good as the data they're trained on, and regulatory acceptance is still evolving. The episode highlights a specific example where VeriSIM's predictions matched actual phase 2 results for a liver disease drug, saving the sponsor an estimated $30 million in trial costs. A concrete look at how biotech is betting on computation to fix a broken R&D model. #VeriSIMLife #AIinClinicalTrials #VirtualPatients #DrugDevelopment #BiotechStartups #ClinicalTrialPrediction #MachineLearning #PharmaR&D #DrugDiscovery #DigitalTwins #Simulation #Phase2Trials #LiverDisease #CostReduction #Business #Technology #FexingoBusiness #BusinessPodcast Keep every episode free: buymeacoffee.com/fexingo